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Abstract: Recently, in February 2020, we published a study exploring the intestinal absorption and
metabolism of oleocanthal (OLC) in rats. A single-pass intestinal perfusion technique (SPIP) was used,
involving simultaneous sampling from the luminal perfusate and mesenteric blood. Later, comments
on our published paper were released, requesting clarification of specific data. In this detailed reply,
we hope to have addressed and clarified all the concerns of A. Kaddoumi and K. El Sayed and that
the scientific community will benefit from both the study and the comments it has generated.
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1. Introduction
We appreciate the interest of A. Kaddoumi and K. El Sayed in our study and thank them
for providing us with the opportunity to make improvements and add some new information.
The following is our response to their comments, which can be divided in two parts, one related to
the oleocanthal (OLC) purity and analysis of the biological samples, and the other concerning the
perfusion technique used in rats.
2. Reply to the Comments
2.1. Purity of Oleocanthal and Biological Sample Analysis
According to the commercial supplier, the OLC has a purity ≥ 90. However, to confirm this,
although it is not described in the paper, the OLC was analyzed using 1H NMR prior to any of the
experimental work (Figure 1).
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structures are plausible. However, given that the medium (transport medium pH 7, 9.7 g/L Hanks’ 64 
Balanced Salt Solution buffered with (4-(2-hydroxyethyl)-1-piperazine ethane sulfonic acid 10 mM) 65 
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Figure 1. NMR spectrum of oleocanthal.
As can be observed in the spectrum, the aromatic signals belonging to the protons H-8′ and H-4′,
and H-5′ and H-7′ are at 7.04 ppm and 6.73 pp , respectively. In hydroxylated OLC, the protons are
not symmetrical and appear at 6.66 ppm (H-4′), 6.71 ppm (H-7′) and 6.55 ppm (H-8′). The signals
corresponding to H-4 ’and H-7′ protons may overlap with our signals, but not that of H-8′, and the
absence of a signal at 6.55 ppm indicates the OLC was not hydroxylated. The protons of aldehydes are
also of diagnostic value. The protons of hydroxylated OLC are described as appearing at 9.19 and
9.54 ppm in acetonitrile, which despite being very close to our signals (just 0.02 ppm away) should be
distinguishable [1].
With respect to hemiacetal and acetal, a study carried out in 2017 [2] showed that the use of
methanol–water solutions for the extraction of phenols (including OLC) did not influence their
formation. In addition, the quantitative responses led to the conclusion that acetonitrile and
ethanol–water had a similar extraction efficiency for phenols in virgin olive oils. Moreover, very low
concentrations of acetals and hemiacetals from OLC were only detected when methanol gradients
under acidic conditions were used for chromatographic separation. Methanol has also previously
been used in solid–liquid extraction of biological fluids, gastrointestinal contents and metabolic tissues
to study differences in the absorption and metabolism of hydroxytyrosol, either in its free form or
through its naturally occurring esterified precursors, oleuropein and oleacein [3], and in biological
samples after the ingestion of a phenolic extract from olive cake (including OLC) [4,5].
Regarding metabolite B, it should be noted that we refer to proposed structures. Indeed,
both structures are plausible. However, given that the medium (transport medium pH 7, 9.7 g/L Hanks’
Balanced Salt Solution buffered with (4-(2-hydroxyethyl)-1-piperazine ethane sulfonic acid 10 mM) is
essentially neutral and includes piperazine, the structure considered wrong by A. Kaddoumi and K.
El Sayed may have more potential to be the correct one (see Reference [6]). Additionally, although water
addition to C=O is evidently possible, the corresponding adducts are generally thermodynamically
unstable and do not accumulate. They can nevertheless act as intermediates leading to more stable
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structures, in this case possibly a pyrane ring via cyclization. Interestingly, both pathways converge to
the same product (a bis-hemiketal) (Figure 2). Therefore, based on the medium used in the reaction,
we conclude that the most likely structure is the one we propose.
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Figure 2. Possible cyclization to a stable pyrane ring.
Although it is true that more polar metabolites generally elute earlier than aglycones in reversed
phase columns, factors other than polarity can affect elution, including molecule size and the pH.
The retention time therefore reflects a compromise between different factors. Thus, while glucuronides
and glucosides are more polar than the corresponding aglycone, they have a high molecular weight,
and many other studies report that glucuronides elute after aglycones [5,7,8].
In their comments, A. Kaddoumi and K. El Sayed also question the fragmentation interpretation.
In mass spectrometry, different equipment and conditions might result in variable fragmentation,
a drawback faced by all mass spectrometrists. We did not detect the ion m/z 121, but nor have other
studies, which report the same mass fragments of OLC as here [9,10]. Figure 3 shows the fragments
that we have postulated for each compound.
A stability study of OLC in blood at 37 ◦C for 5 min, which is the time that OLC was in contact with
blood in each sample, was not performed. However, we did not detect any OLC hydrolysis products in
plasma during this time. It should be mentioned that the blood was kept in ice slush immediately after
collection, and then centrifuged at 4 ◦C for 5 min and stored at −80 ◦C. Thus, either these conditions
were not the most favorable for blood esterase activity, or hydrolysis did not occur, at least not in our
experimental conditions (the evaluation could have been carried out in the intestine, where esterases
are also distributed) [11]. OLC incubation in blood at 37 ◦C for a longer time (1 h) could provide more
information about the potential hydrolysis mentioned in the comments, as well as about a possible
distribution to erythrocytes, and will be taken into account in future studies.
Finally, our aim was not molecular elucidation but to study the intestinal absorption and
metabolism of OLC using an in situ perfusion technique in rats. Due to its complexity and
diversity, successful structural elucidation requires an array of complementary analytical technologies.
Furthermore, the isolation of these metabolites from plasma is difficult, resulting in only small quantities.
In the literature, there are no NMR studies of OLC in blood and urine, since the concentrations in
biological samples are too low for this technology.
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2.2. Perfusion Technique
Equation (1) of the paper contains a typing error: the negative sign should be removed. However,
the equation used for the calculations is correct (confirmed after reviewing the spreadsheets and














The equation used to correct the OLC concentration in the intestinal lumen (Equation (2)) is also
correct [12–16].




Roos et al. 2017 [17,18], based on the work of Sutton and Rinaldi [19], use the same equation but
adding the correction factor of 1.15 (Equation (3)):




Sutton and Rinaldi carried out a comparative study of gravimetric, phenol red (PR) and
14C-PEG4000-3350 methods to determine water absorption in the rat single-pass intestinal perfusion
(SPIP) model. They concluded that the gravimetric method for correcting water flux is as accurate
as the two “non-absorbed” marker methods. They also reported that the average water flux (WF)
for 10 compounds by either gravimetric or PR methods was 75.3 and 65.41 mL/h/cm, respectively,
giving a WFgrav/WFPR ratio = 1.15 (correction factor of Equation (3)). However, this correction factor
was obtained only for n = 3 animal preparations per compound and showed high variability. As an
illustration, when using the PR method, the values of WF range between −21.7 and 133.8 mL/h/cm.
Omitting the negative value of −21.7 (the only negative value among all the data), the ratio changes to
0.987. Thus, the correction factor of 1.15 is very sensitive, and its statistical confirmation would require
more data. Tuğcu Demiröz et al. [20] also found a slightly lower estimation of the water reabsorption
coefficient with the PR method, but this difference did not affect the estimation of the absorption rate
coefficient of the assayed drugs. Therefore, in our opinion, Equations (2) and (3), both of which are
currently being used by numerous researchers, are correct, and the lower than expected levofloxacin
(LEV) permeability has other explanations (some noted in the paper). As far as we know, only one
study has been published on the intestinal permeability of LEV in rats, which unfortunately is available
only in Chinese [21]. The study of Volpe D.A. concerning to permeability of fluoroquinolones and
cited in our paper [22] was carried out in a different model (in vitro and not in vivo; static vs. perfusion
model), and different physiological factors can influence the results. To obtain further information,
LEV and OLC should be tested in vitro on Caco-2 cells under the same experimental conditions,
as interlaboratory variability is also possible. Accordingly, the results for LEV cannot be considered
invalid and/or inconsistent. In addition, further investigation of LEV permeability in the SPIP model
in rats would be the subject of another study and was not the aim of the present work. In our study,
the highly permeable LEV was used only as a reference and for comparative purposes. Nevertheless,
it would have been interesting to include a second reference standard (of low permeability).
The terms “amphiphilia” and “lipophilia” are not contradictory and express different molecular
properties. In the context of our work, in which the permeability of a compound was studied,
lipophilia is more appropriate, being a good predictor of intestinal permeability [23]. A common
measure of the lipophilicity of a substance is its partitioning between n-octanol and water [24], and a
hyperbolic relationship between lipophilia, expressed as logP, and intestinal absorption is described [25].
Such relationships are very important. OLC has a logarithm of the partition coefficient (logP) of 1.15
(similar to that of metoprolol log, P = 1.73), that is, a lipophilic property, which together with its low
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molecular weight, constitute favorable properties for its transport through the intestinal membrane by
passive mechanisms. For this reason, OLC is considered to have a relatively high lipophilicity.
On the other hand, regarding OLC solubility, Qusa et al. 2019 [26] and Siddique et al. 2019 [27],
reported a solubility of 400–500 µg/mL, which according to Wolk et al. 2014 [23] indicates that OLC
is “very slightly soluble”. Accordingly, there is no contradiction. We agree with A. Kaddoumi and
K. El Sayed that OLC is soluble in water at the studied concentration (0.1 mg/mL). In fact, this is a
requirement for the methodology used in the intestinal permeability study and guarantees a correct
determination of intestinal permeability without solubility limitations. In the “Results and Discussion”
section, the following statement appears: “According to its physicochemical properties (low solubility
and relatively high lipophilicity), this compound meets the characteristics of BCS class 2”. This statement
is based on the physicochemical properties of OLC, and while there is no contradiction regarding its
solubility and lipophilicity (bibliographic data), from a regulatory point of view, there is insufficient
information to affirm that OLC belongs to class 2. Certainly, the solubility should be determined at
37 ◦C, within the range of physiological pH of the intestinal tract (pH 1.2-4.5-6.8) and also at the dose
number [28,29]. However, it must be noted that such determinations are currently impracticable due
to the scarcity of the product and suppliers, and its high cost. The aforementioned biopharmaceutics
classification (BCS) based on solubility and lipophilic properties was only “provisional” and without
regulatory pretensions. In the context of the present work and state of the art of OLC research,
the intention was to enrich the discussion and explain the obtained permeability results.
Elsewhere in their comments, A. Kaddoumi and K. El Sayed question how the samples were
collected, focusing on the statement, “the outflow perfusate was collected in 1.5 mL amber vials at
5 min intervals for 60 min”. We agree that the sample collection should be described in more detail.
To be more precise, the output perfusate was collected in several 1.5 mL amber vials because at the
time of conducting the experiment, and to avoid isomerization at that moment, we only had available
1.5 mL amber Eppendorfs to take to the animal facilities laboratory. We realize that it would have been
more practical to collect the samples directly in 5-mL amber tubes, but these were unavailable at the
time. The remaining sample manipulation was done in our laboratory under infrared light conditions:
the aliquots were centrifuged (7516 g for 10 min at 4 ◦C), the supernatant was transferred to 5-mL
volume tubes and mixed, and the samples were stored at −80 ◦C until analysis. We have acquired
5-mL amber tubes for future experiments.
The perfusion flow rate used in the study (1 mL/min), while not the most frequent, has been
used by other authors [30]. We agree that this factor can affect the intestinal residence time of the
compounds tested and their absorption. However, to facilitate the interpretation of the obtained
results, a parallel study was conducted with a highly permeable compound, tested under the same
experimental conditions.
Finally, in the conclusions, we noted, “previous research has indicated that higher levels of
OLC reach human plasma than in rats [11]”, taken from Lenerma’s study [31]. In this preclinical
study, we did not provide human data, and with this statement, we only wished to refer to the fact
that permeability values are usually higher in humans than in rats. We apologize if the wording is
insufficiently clear.
3. Conclusions
We would like to conclude this reply with the following remarks: (i) OLC is a very interesting and
promising constituent of extra virgin olive oil in terms of health and is still underexplored; (ii) this
is the first in vivo study of OLC in rats, which (iii) can serve as a starting point for future research.
We hope that the scientific community will benefit from this study and the comments it has generated.
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